Metabolon expands multi-study agreement with Mitsubishi Tanabe

The expanded partnership will give researchers at Mitsubishi Tanabe preferred access to Metabolon’s global biochemical profiling services.

Completing research studies using Metabolon’s services, Mitsubishi Tanabe has gained insight into new drugs and streamlined their development. As part of the new agreement, Mitsubishi Tanabe has committed several upcoming research studies to Metabolon.

John Ryals, president and CEO of Metabolon, said: “Expanding relationships like this one with Mitsubishi Tanabe is continued validation of Metabolon’s ability to impact the development of drugs and diagnostics.”